Loading...
•
Sep 30, 2020
Vanda Q3 2020 Earnings Report
Vanda reported a slight increase in total net product sales and advanced its clinical development pipeline.
Key Takeaways
Vanda Pharmaceuticals reported a 1% increase in total net product sales for Q3 2020 compared to Q3 2019, with $60.3 million in sales. The company's income before taxes was $8.4 million, and net income was $5.9 million. The HETLIOZ® Smith-Magenis Syndrome marketing authorization applications were accepted by the FDA for priority review.
Total net product sales were $60.3 million, a 1% increase compared to Q3 2019.
HETLIOZ® net product sales increased by 5% to $39.6 million compared to Q3 2019.
Fanapt® net product sales decreased by 6% to $20.7 million compared to Q3 2019.
Income before taxes was $8.4 million, compared to $12.3 million in Q3 2019.
Revenue by Segment
Forward Guidance
Vanda will continue to assess the impact of the evolving pandemic on its business and operations and will provide future updates to its financial guidance as necessary.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...